Vaccinex is committed to innovation in the way we approach drug discovery and development.

Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and other targeted biological therapies. A Vaccinex antibody product is currently in clinical trials for immunotherapy of cancer and to prevent or delay the onset of neurodegenerative Huntington’s disease.

Learn more about our company




Vaccinex has discovered and developed an immune-modulating, anti-semaphorin 4D (SEMA4D) antibody that has been shown in preclinical studies to regulate the infiltration of immune cells into the tumor microenvironement. Specifically, anti-SEMA4D induces an increase in tumor-specific cytotoxic T cells and a change in the balance of tumoricidal and regulatory macrophage toward a pro-inflammatory, anti-tumorigenic response.

Learn more about VX15 for Immuno-Oncology




Huntington’s disease (HD) is a devastating neurodegenerative disease that results in uncontrolled movements and debilitating cognitive and behavioral changes. It is thought that chronic activation of astrocytes and microglia, the natural inflammatory cells of the brain, may contribute importantly to the degenerative process in this and other neurological disorders. Vaccinex is investigating the ability to protect neurons from degeneration and to effectively prevent or delay the onset of this genetically determined disease by blocking the inflammatory response of astrocytes and microglia.

Vaccinex Sponsored a Key Opinion Leader (KOL) Luncheon on Huntington’s Disease

A Key Opinion Leader (KOL) Luncheon on Huntington's Disease (HD) was hosted by Vaccinex on February 6, 2018. The meetings featured presentations by Ira Shoulson, MD, (Georgetown University), Karl Kieburtz, MD, MPH (University of Rochester), and Maurice Zauderer, Ph.D. (Vaccinex, Inc.) who provided an update on the Company's SIGNAL trial (Phase 2 study of investigational VX15/2503 antibody in HD). Discussion included recent research and the current treatment landscape, as well as the unmet medical need for treating patients with Huntington's Disease.

To see and hear a replay of the KOL Luncheon, please click here to register or log in.

Learn more about VX15 for Neurology

technology platform


ActivMAb® is Vaccinex’s antibody discovery and optimization platform. ActivMAb® combines the advantages of both viral panning and cell sorting to enable the efficient identification of high-affinity, fully human antibodies from antibody libraries expressed in mammalian cells. A fusion protein of immunoglobulin heavy chain with a vaccinia membrane protein (Ig-VMP) has been developed that enables efficient expression on the surface of vaccinia virus, an enveloped mammalian virus, as well as on the surface of the infected cell.

Learn more about ActivMAb®